In the latest quarter, 11 analysts provided ratings for Glaukos (NYSE:GKOS), showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Analysts have set 12-month price targets for Glaukos, revealing an average target of $143.82, a high estimate of $200.00, and a low estimate of $86.00. A decline of 10.26% from the prior average price target is evident in the current average.

Exploring Analyst Ratings: An In-Depth Overview

A clear picture of Glaukos's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

To gain a panoramic view of Glaukos's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Glaukos analyst ratings.

About Glaukos

Glaukos: A Financial Overview

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Positive Revenue Trend: Examining Glaukos's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.1% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -17.01%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): Glaukos's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -2.37%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Glaukos's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.87%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Glaukos's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.

The Basics of Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.